Abstract:Radiotherapy is one of the important treatment methods for brain tumors or brain metastases, which improves the survival time of patients and inevitably exposes them to the risk of radiation brain injury (RBI). Radiation-induced damage to the central nervous system includes focal brain necrosis, cognitive deficits and cerebrovascular diseases, and treatment options are limited [ 1 ]. The pathogenesis of radiation-induced brain injury is not clear which may involve vascular endothelial cell injury, glial cell injury and autoimmune inflammatory reaction [ 2 , 3 ]. Animal model studies have found that radiation can cause vascular endothelial growth factor (VEGF) over-expression, resulting in increased permeability of vascular endothelial cells, decreased density of microvessels in the brain tissue, destroyed the integrity of the blood–brain barrier (BBB) and caused cerebral edema [ 4–6 ]. At the same time, radiation-induced cell damage can also mediate the occurrence of tissue inflammation and infiltration of macrophages and lymphocytes and increase the secretion of a variety of inflammatory factors (including interleukin [IL]-1β, IL-6, IL-8 and tumor necrosis factor-α (TNF-α), etc.). Thus maintaining and enhancing the inflammatory state and continuously damaging the brain tissue [ 7 , 8 ].

Reduction of acute radiation-induced brain injury in rats by anlotinib